SK bioscience CEO Jaeyong Ahn (left) and Novavax president and CEO John Jacobs pose after signing the strategic partnership agreement. Credit: SK bioscience / PRNewswire.

SK bioscience has announced plans to purchase Novovax shares via an equity investment of $85m through a private placement.

Its board of directors decided to acquire 6.5 million shares of common stock of the protein-based vaccine developer at $13 per share.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The companies formed a CMO/CDMO [contract manufacturing organisation/contract development and manufacturing organisation] alliance during the Covid-19 pandemic. Now that the disease is endemic, their strategy is to evolve toward a longstanding collaboration

The companies have extended an existing licence agreement by including a modified Covid-19 vaccine from Novavax.

This vaccine is being developed for annual inoculation drives. 

See Also:

Under the extended deal, SK bioscience will now gain exclusive rights to supply and market the Covid-19 variant vaccine in South Korea and non-exclusive rights in Thailand and Vietnam.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Leveraging variant strain antigens and the Matrix-M adjuvant of Novavax, the company will carry out the production and marketing of pre-filled syringes containing drug and vaccine products.

The companies will also explore partnerships using the Matrix-M adjuvant.

SK bioscience CEO Jaeyong Ahn stated: “We believe that the strategic equity investment and the continuous co-operation between SK bioscience and Novavax, which are among the few companies that focused on developing Covid-19 vaccines during the pandemic, will create a powerful synergy. 

“SK bioscience is focused on developing a successful global cooperative model in terms of company growth, health promotion and response to the next pandemic.”

In July 2023, SK bioscience signed a memorandum of understanding with the Government Pharmaceutical Organisation (GPO) to boost vaccine infrastructure in Thailand.